Compare STEM & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STEM | BNR |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 76.5M |
| IPO Year | 2020 | 2019 |
| Metric | STEM | BNR |
|---|---|---|
| Price | $6.98 | $10.90 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | ★ 95.6K | 24.5K |
| Earning Date | 05-06-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | N/A |
| Revenue This Year | $2.77 | $111.65 |
| Revenue Next Year | $14.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $6.70 | $4.75 |
| 52 Week High | $32.23 | $41.72 |
| Indicator | STEM | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 55.89 |
| Support Level | N/A | $8.05 |
| Resistance Level | $8.39 | $13.89 |
| Average True Range (ATR) | 0.48 | 0.93 |
| MACD | -0.00 | 0.66 |
| Stochastic Oscillator | 15.32 | 67.49 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.